- Previous Close
265.82 - Open
241.99 - Bid 237.65 x 900
- Ask 240.10 x 800
- Day's Range
241.99 - 241.99 - 52 Week Range
241.99 - 359.22 - Volume
4 - Avg. Volume
41 - Market Cap (intraday)
6.814B - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
-- - EPS (TTM)
-65.36 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
www.bio-rad.comRecent News: BIO-B
View MorePerformance Overview: BIO-B
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIO-B
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIO-B
View MoreValuation Measures
Market Cap
6.81B
Enterprise Value
6.52B
Trailing P/E
--
Forward P/E
26.32
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.66
Price/Book (mrq)
1.03
Enterprise Value/Revenue
2.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-71.86%
Return on Assets (ttm)
1.55%
Return on Equity (ttm)
-24.09%
Revenue (ttm)
2.57B
Net Income Avi to Common (ttm)
-1.84B
Diluted EPS (ttm)
-65.36
Balance Sheet and Cash Flow
Total Cash (mrq)
1.66B
Total Debt/Equity (mrq)
20.93%
Levered Free Cash Flow (ttm)
180.86M